FDA gives OK to Lupin’s Lidex generic

SILVER SPRING, Md. — The Food and Drug Administration has approved Lupin’s generic of Lidex (fluocinonide topical solution, 0.05%), the company recently announced.

The drug is indicated to relieve inflammatory and pruritic manifestations of dermatoses that are responsive to corticosteroid treatment. The drug had U.S. sales of $32.4 million for the 12 months ended March 2017, according to QuintilesIMS data.